Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Magic:_The_Gathering_set
|
| gptkbp:activities |
Beta-adrenergic receptor antagonist
|
| gptkbp:appointed_by |
Intravenous injection
Oral tablet |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Inderal
gptkb:Inno_Pran |
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
Asthma
Heart block Severe bradycardia Cardiogenic shock |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:discovered_by |
1960s
|
| gptkbp:excretion |
Urine
|
| gptkbp:formulation |
Extended-release tablet
Topical solution Oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Propranolol
|
| gptkbp:indication |
Anxiety disorders
Hypertrophic cardiomyopathy Post-myocardial infarction Pheochromocytoma Thyrotoxicosis |
| gptkbp:ingredients |
C16 H21 N O3
|
| gptkbp:interacts_with |
gptkb:Clonidine
gptkb:Digoxin Calcium channel blockers Antidepressants |
| gptkbp:is_available_on |
Generic medication
|
| gptkbp:is_used_for |
gptkb:Anxiety
gptkb:Tremors Hypertension Migraine prevention |
| gptkbp:lifespan |
3 to 6 hours
|
| gptkbp:metabolism |
Liver
|
| gptkbp:side_effect |
gptkb:Depression
gptkb:Nausea Dizziness Fatigue Shortness of breath Bradycardia Hypotension Sleep disturbances Cold extremities |
| gptkbp:treatment |
Hypertension
Performance anxiety Migraine prophylaxis |
| gptkbp:type_of |
525-66-6
|
| gptkbp:bfsParent |
gptkb:Sir_James_Black
|
| gptkbp:bfsLayer |
5
|